Citations

Showing 10 of 108119 citations.

JAK2 wild-type erythrocytosis associated with sodium-glucose cotransporter 2 inhibitor therapy
Gangat, Naseema , Al‐Kali, Aref , Pardanani, Animesh , Tefferi, Ayalew , Szuber, Natasha , Alkhateeb, Hassan B.

Mayo Clinic

Blood | October 15, 2021 | Volume: 138 | Issue: 26 | Pages: 2886-2889

10.1182/blood.2021013996 | PMID 34653249 Get It

To the Editor: Let's Make “Provider” a Dirty Word
Staab, Jeffrey P.

Mayo Clinic

Journal of Graduate Medical Education | October 15, 2021 | Volume: 13 | Issue: 5 | Pages: 736-736

10.4300/jgme-d-21-00453.1 | PMID 34721810 Get It

Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Children's Oncology Group Report
Leavey, Patrick J. , Laack, Nadia N. , Krailo, Mark D., Buxton, Allen, Randall, R. Lor , DuBois, Steven G. , Reed, Damon R. , Grier, Holcombe E., Hawkins, Douglas S. , Pawel, Bruce, Nadel, Helen , Womer, Richard B. , Letson, G. Douglas, Bernstein, Mark, Brown, Kenneth, Maciej, Alexis, Chuba, Paul, Ahmed, Atif A., Indelicato, Daniel J. , Wang, Dian, Marina, Neyssa , Janeway, Katherine A. , Mascarenhas, Leo , Gorlick, Richard , Janeway, Katherine A , Mascarenhas, Leo , Laack, Nadia N Issa , Hawkins, Douglas S , Reed, Damon R , Randall, Robert Lor , Indelicato, Daniel J , Leavey, Patrick , Krailo, Mark D., Buxton, Allen, DuBois, Steven G , Grier, Holcombe E., Pawel, Bruce, Nadel, Helen , Womer, Richard , Letson, G. Douglas, Bernstein, Mark, Brown, Kenneth, Maciej, Alexis, Chuba, Paul, Ahmed, Atif A., Wang, Dian, Marina, Neyssa

Mayo Clinic

Journal of Clinical Oncology | October 15, 2021 | Volume: 39 | Issue: 36 | Pages: 4029-4038

10.1200/jco.21.00358 | PMID 34652968 Get It

PURPOSE The primary aim of this phase III randomized trial was to test whether the addition of vincristine, topotecan, and cyclophosphamide (VTC) to interval compressed chemotherapy improved survival outcomes for patients with previously untreated nonmetastatic Ewing sarcoma. METHODS Patients were randomly assigned to receive standard five-drug interval compressed chemotherapy (regimen A) for 17 cycles or experimental therapy with five cycles of VTC within the 17 cycles (regimen B). Patients were stratified by age at diagnosis (< 18 years and ≥18 years) and tumor site (pelvic bone, nonpelvic bone, and extraosseous). Tumor volume at diagnosis was categorized as < 200 mL or ≥ 200 mL. Local control occurred following six cycles. Histologic response was categorized as no viable or any viable tumor. Event-free survival (EFS) and overall survival (OS) were compared between randomized groups with stratified log-rank tests. RESULTS Of 642 enrolled patients, 309 eligible patients received standard and 320 received experimental therapy. The 5-year EFS and OS were 78% and 87%, respectively. There was no difference in survival outcomes between randomized groups (5-year EFS regimen A v regimen B, 78% v 79%; P = .192; 5-year OS 86% v 88%; P = .159). Age and primary site did not affect the risk of an EFS event. However, age ≥ 18 years was associated with an increased risk of death at 5 years (hazard ratio 1.84; 95% CI, 1.15 to 2.96; P = .009). The 5-year EFS rates for patients with pelvic, nonpelvic bone, and extraosseous primary tumors were 75%, 78%, and 85%, respectively. Tumor volume ≥ 200 mL was significantly associated with lower EFS. CONCLUSION While VTC added to five-drug interval compressed chemotherapy did not improve survival, these outcomes represent the best survival estimates to date for patients with previously untreated nonmetastatic Ewing sarcoma.
Survival outcomes and prognostic analysis in triple-negative invasive lobular carcinoma: A SEER database study
Joshi, Utsav , Yadav, Sumeet Kumar, Yadav, Siddhartha

Mayo Clinic

International Journal of Cancer Care and Delivery | October 15, 2021 | Volume: 1 | Issue: Supplement 1 | Pages: No page available

10.53876/001c.28395 Get It

Comparison of the Distribution of Oncotype Dx Recurrence Scores Between Invasive Ductal Carcinoma and Invasive Lobular Carcinoma of the Breast
Yadav, Sumeet Kumar, Yadav, Siddhartha

Mayo Clinic

International Journal of Cancer Care and Delivery | October 15, 2021 | Volume: 1 | Issue: Supplement 1 | Pages: No page available

10.53876/001c.28398 Get It

Development of a MicroRNA Signature Predictive of Recurrence and Survival in Pancreatic Ductal Adenocarcinoma
Sebastian, Nikhil , Merrell, Kenneth W. , Zhang, Lizhi , Wilhite, T.J., Elganainy, Dalia , Cloyd, Jordan M. , Dillhoff, Mary , Tsung, Allan , Abushahin, Laith , Williams, Terence M. , Chen, Wei , Elganainy, Dalia , Abushahin, Laith , Williams, Terence M , Chen, Wei , Webb, Amy , Koay, Eugene J. , Wolfe, Adam R. , Robb, Ryan N. , Chen, Wei , Noonan, Anne M.

Mayo Clinic

Cancers | October 15, 2021 | Volume: 13 | Issue: 20 | Pages: 5168

10.3390/cancers13205168 | PMID 34680317 Get It

Background: Optimal patient selection for radiotherapy in pancreatic ductal adenocarcinoma (PDAC) is unestablished. Molecular profiling may select patients at high risk for locoregional recurrence (LRR) who would benefit from radiation. Methods: We included resectable pancreatic cancer (R-PDAC) patients, divided into training and validation cohorts, treated among three institutions with surgery and adjuvant chemotherapy, and borderline resectable or locally advanced pancreatic cancer (BR/LA-PDAC) patients treated with chemotherapy with or without radiation at the primary study institution. We isolated RNA from R-PDAC surgical specimens. Using NanoString, we identified miRNAs differentially expressed between normal and malignant pancreatic tissue. ElasticNet regression identified two miRNAs most predictive of LRR in the training cohort, miR-181b/d and miR-575, which were used to generate a risk score (RS). We evaluated the association of the median-dichotomized RS with recurrence and overall survival (OS). Results: We identified 183 R-PDAC and 77 BR/LA-PDAC patients with median follow up of 37 months treated between 2001 and 2014. On multivariable analysis of the R-PDAC training cohort (n = 90), RS was associated with worse LRR (HR = 1.34; 95%CI 1.27–11.38; p = 0.017) and OS (HR = 2.89; 95%CI 1.10–4.76; p = 0.027). In the R-PDAC validation cohort, RS was associated with worse LRR (HR = 2.39; 95%CI 1.03–5.54; p = 0.042), but not OS (p = 0.087). For BR/LA-PDAC, RS was associated with worse LRR (HR = 2.71; 95%CI 1.14–6.48; p = 0.025), DR (HR = 1.93; 95%CI 1.10–3.38; p = 0.022), and OS (HR = 1.97; 95%CI 1.17–3.34; p = 0.011). Additionally, after stratifying by RS and receipt of radiation in BR/LA-PDAC patients, high RS patients who did not receive radiation had worse LRR (p = 0.018), DR (p = 0.006), and OS (p < 0.001) compared to patients with either low RS or patients who received radiation, irrespective of RS. Conclusions: RS predicted worse LRR and OS in R-PDAC and worse LRR, DR, and OS in BR/LA-PDAC. This may select patients who would benefit from radiation and should be validated prospectively.
Recovery Model Implementation for a Medical/Geriatric Psychiatric Unit to Decrease Restraint and Seclusion Episodes: A Quality Improvement Project
Ayres, Sara , Tracy, Mary Fran , Ayres, Sara

Mayo Clinic

Journal of the American Psychiatric Nurses Association | October 15, 2021 | Volume: 27 | Issue: 5 | Pages: 355-360

10.1177/10783903211048449 | PMID 34651520 Get It

Introduction: In inpatient behavioral health units, a long-standing behavioral management controversy has been whether to physically restrain or seclude patients. The rate of restraint use at the institution underperformed compared with the national average, which led to the project implementation. Aims: This quality improvement project’s objective was to decrease restraint and seclusion use, improve quality of care, and decrease cost through implementation of recovery model principles. Method: Implementation started in October 2019 on a 14-bed inpatient medical/geriatric psychiatric unit with 38 psychiatric RNs at a large academic medical center. The project was a pre–post implementation design with interventions consisting of staff education, RN language observation, and orientation toolkit development. Changes in staff knowledge were measured by Recovery Knowledge Inventory surveys at baseline, 1 week posteducation, and 4 months posteducation. Restraint and seclusion use data were analyzed 3 months preimplementation and 3 months postimplementation. Results: Staff knowledge of the recovery model increased from baseline to 1 week postimplementation in all four survey domains (range = 6% to 9% improvement). While improvements were maintained in two survey domains, two domains of staff knowledge showed slight declines (1% to 2% decline in scores) 4 months postintervention. Restraint use decreased 73.1% and seclusion use decreased 16.3% from pre to postintervention. Conclusion: Implementation of recovery model principles can decrease restraint and seclusion episodes, which increases quality and decreases cost to the organization.
Targeting LRRC15 Inhibits Metastatic Dissemination of Ovarian Cancer
Ray, Upasana, Jung, Deok-Beom, Jin, Ling, Xiao, Yinan , Dasari, Subramanyam, Bhattacharya, Sayantani Sarkar , Thirusangu, Prabhu, Staub, Julie , Roy, Debarshi, Roy, Bhaskar, Weroha, S. John, Hou, Xiaonan, Purcell, James W., Bakkum-Gamez, Jamie N., Mitra, Anirban K., Shridhar, Viji, Thirusangu, Prabhu , Dasari, Subramanyam , Ray, Upasana , Sarkar Bhattacharya, Sayantani , Staub, Julie K , Kaufmann, Scott H , Kannan, Nagarajan , Ray, Upasana, Jung, Deok-Beom, Jin, Ling, Xiao, Yinan , Thirusangu, Prabhu, Roy, Debarshi, Roy, Bhaskar, Weroha, S. John, Hou, Xiaonan, Purcell, James W., Bakkum-Gamez, Jamie N., Mitra, Anirban K., Shridhar, Viji

Mayo Clinic

Cancer Research | October 15, 2021 | Volume: 82 | Issue: 6 | Pages: 1038-1054

10.1158/0008-5472.can-21-0622 | PMID 34654724 Get It

Abstract Dissemination of ovarian cancer cells can lead to inoperable metastatic lesions in the bowel and omentum that cause patient death. Here we show that LRRC15, a type-I 15-leucine–rich repeat-containing membrane protein, highly overexpressed in ovarian cancer bowel metastases compared with matched primary tumors and acts as a potent promoter of omental metastasis. Complementary models of ovarian cancer demonstrated that LRRC15 expression leads to inhibition of anoikis-induced cell death and promotes adhesion and invasion through matrices that mimic omentum. Mechanistically, LRRC15 interacted with β1-integrin to stimulate activation of focal adhesion kinase (FAK) signaling. As a therapeutic proof of concept, targeting LRRC15 with the specific antibody–drug conjugate ABBV-085 in both early and late metastatic ovarian cancer cell line xenograft models prevented metastatic dissemination, and these results were corroborated in metastatic patient-derived ovarian cancer xenograft models. Furthermore, treatment of 3D-spheroid cultures of LRRC15-positive patient-derived ascites with ABBV-085 reduced cell viability. Overall, these data uncover a role for LRRC15 in promoting ovarian cancer metastasis and suggest a novel and promising therapy to target ovarian cancer metastases. Significance: This study identifies that LRRC15 activates β1-integrin/FAK signaling to promote ovarian cancer metastasis and shows that the LRRC15-targeted antibody–drug conjugate ABBV-085 suppresses ovarian cancer metastasis in preclinical models.
Personalized Therapy: Can it Tame the COVID-19 Monster?
Arish, Mohd , Naz, Farha

Mayo Clinic

Personalized Medicine | October 15, 2021 | Volume: 18 | Issue: 6 | Pages: 583-593

10.2217/pme-2021-0077 | PMID 34649460 Get It

Long-term surgical outcomes of intracranial epidermoid tumors: impact of extent of resection on recurrence and functional outcomes in 63 patients
Vakharia, Kunal , Driscoll, Colin L. W., Carlson, Matthew L. , Meyer, Fredric B. , Link, Michael J., Hasegawa, Hirotaka , Carlstrom, Lucas P. , Gompel, Jamie J. Van , Link, Michael J.

Mayo Clinic

Journal of Neurosurgery | October 15, 2021 | Volume: 136 | Issue: 6 | Pages: 1592-1600

10.3171/2021.5.jns21650 | PMID 34653989 Get It

OBJECTIVE The authors’ objective was to reevaluate the role of microsurgery for epidermoid tumors by examining the associations between extent of resection (EOR), tumor control, and clinical outcomes. METHODS This was a retrospective study of patients with microsurgically treated intracranial epidermoid tumors. The recurrence-free and intervention-free rates were calculated using the Kaplan-Meier method. EOR was graded as gross-total resection (GTR) (total resection without residual on MRI), near-total resection (NTR) (a cyst lining was left in place), subtotal resection (STR) (> 90% resection), and partial resection (PR) (any other suboptimal resection) and used to stratify outcomes. RESULTS Sixty-three patients with mean clinical and radiological follow-up periods of 87.3 and 81.8 months, respectively, were included. Sixteen patients underwent second resections, and 5 underwent third resections. The rates of GTR/NTR, STR, and PR were 43%, 35%, and 22%, respectively, for the initial resections; 44%, 13%, and 44% for the second resections; and 40%, 0%, and 60% for the third resections (p < 0.001). The 5- and 10-year cumulative recurrence-free rates after initial resection were 64% and 32%, respectively. When stratified according to EOR, the 10-year recurrence-free rate after GTR/NTR was marginally better than that after STR (61% vs 35%, p = 0.130) and significantly better than that after PR (61% vs 0%, p < 0.001). The recurrence-free rates after initial microsurgery were marginally better than those after second surgery (p = 0.102) and third surgery (p = 0.065). The 5- and 10-year cumulative intervention-free rates after initial resection were 91% and 58%, respectively. When stratified according to EOR, the 10-year intervention-free rate after GTR/NTR was significantly better than that after STR (100% vs 51%, p = 0.022) and PR (100% vs 27%, p < 0.001). The 5-year intervention-free rate after initial surgery was marginally better than that after second surgery (52%, p = 0.088) and significantly better than that after third surgery (0%, p = 0.004). After initial, second, and third resections, permanent neurological complications were observed in 6 (10%), 1 (6%), and 1 (20%) patients, respectively. At the last follow-up visit, 82%, 23%, and 7% of patients were free from radiological recurrence after GTR/NTR, STR, and PR as the initial surgical procedure, respectively. CONCLUSIONS GTR/NTR seems to contribute to better disease control without significantly impairing functional status. Initial resection offers the best chance to achieve better EOR, leading to better disease control.